ロード中...
Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial
OBJECTIVE: To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. RESEARCH DESIGN AND METHODS: Patients (n = 368; A1C ≥7%) were randomized to 20 mg/day rimonabant or placebo in this 48-week...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Diabetes Association
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2827517/ https://ncbi.nlm.nih.gov/pubmed/20009090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-0455 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|